Notícias e Atividades da Crispr Therapeutics
Presença
Crispr Therapeutics é uma empresa listada sob o símbolo CRSP (CH).
Executivos
Veja o organograma con seus 19 executivos principais
Biografias mais buscadas da Crispr Therapeutics
- Samarth Kulkarni, Chief Executive Officer and Chairman of the Board
- Simeon George, Director
- Edd Fleming, Director
Recentes movimentos de executivos em Crispr Therapeutics
- Julianne Bruno, Chief Operating Officer, deixará a Companhia em 26 de mai. de 2025 (Notícia publicada em 27 de março de 2025).
- Briggs Morrison, ingressou na Companhia como Director (Notícia publicada em 8 de janeiro de 2025).
Criar um alerta
para seguir os movimentos de executivos da Crispr Therapeutics.
Biotecnologia
Crispr Therapeutics possui 2.347 concorrentes concorrentes Eurofins (Luxemburgo), Lonza (Suíça) e Johnson & Johnson Innovative Medicine DIA (Estados Unidos).
Popular M&A news in Biotecnologia
- Attovia Therapeutics acaba de anunciar uma arrecadação de fundos de 90 milhões de dólares. (publicado em 21 de abril de 2025).
- Transcarent and Accolade have merged (publicado em 9 de abril de 2025)..
- Kashiv BioSciences acaba de anunciar uma arrecadação de fundos de 150 milhões de dólares. (publicado em 7 de abril de 2025).
Outros contatos sugeridos na indústria do Biotecnologia
Notícias
Últimos comunicados de imprensa de Crispr Therapeutics
- Vertex and CRISPR Therapeutics Present New Data on More Patients With Longer Follow-Up Treated With exagamglogene autotemcel (exa-cel) at the 2022 European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics to Present at the Goldman Sachs 43rd Annual Global Healthcare Conference | CRISPR Therapeutics
- Vertex and CRISPR Therapeutics Announce Acceptance of Late-Breaking Abstract for CTX001™ at the 2022 Annual European Hematology Association (EHA) Congress | CRISPR Therapeutics
- CRISPR Therapeutics to Host Innovation Day on June 21, 2022 | CRISPR Therapeutics
- CRISPR Therapeutics Reports Positive Top-Line Results from Its Phase 1 CARBON Trial of CTX110™ in Relapsed or Refractory CD19+ B-cell Malignancies | CRISPR Therapeutics
- CRISPR Therapeutics Congratulates Co-Founder Emmanuelle Charpentier on Receiving the 2020 Nobel Prize in Chemistry | CRISPR Therapeutics
- CRISPR Therapeutics to Participate in Upcoming Investor Conferences | CRISPR Therapeutics
- CRISPR Therapeutics and Vertex Pharmaceuticals Announce Priority Medicines (PRIME) Designation Granted by the European Medicines Agency (EMA) to CTX001™ for the Treatment of Sickle Cell Disease | CRISPR Therapeutics
- CRISPR Therapeutics to Present at the Wells Fargo 2020 Virtual Healthcare Conference | CRISPR Therapeutics
- View more press releases Close
Redes sociais sobre Crispr Therapeutics
- Crispr Therapeutics na Wikipedia, Google News e Yahoo Finance
- Crispr Therapeutics na LinkedIn, Twitter e YouTube
